Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

Anti-hepatitis B virus activities of natural products and their antiviral mechanisms

Antiviral Natural Products Against Chronic Hepatitis B: Recent Developments

Natural Products: Review for Their Effects of Anti-HBV

Metabolites from traditional Chinese botanical drugs with anti-hepatitis B virus activity - a review

Cytokines and Chemokines in HBV Infection

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Current trends and advances in antiviral therapy for chronic hepatitis B

Novel Approaches Towards Conquering Hepatitis B Virus Infection

HBV life cycle and novel drug targets

New Insights into Hepatitis B Virus Biology and Implications for Novel Antiviral Strategies

The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges

New advances in drug therapy of chronic hepatitis B infection

Traditional Chinese medicine and related active compounds: a review of their role on hepatitis B virus infection

Emerging Antivirals for the Treatment of Hepatitis B

Progress of Infection and Replication Systems of Hepatitis B Virus

Development of novel therapeutics for chronic hepatitis B

Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics

Interplay between hepatitis B virus and the type Ⅰ interferon system and new therapeutic strategies

An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B